Lantern Pharma's Open-Medicine AI to Host Webinar on AI-Driven Oncology Platform and Business Model

Austin-based Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence and genomic data to develop precision oncology therapies, announced that its wholly owned subsidiary, Open-Medicine AI, will host a live webinar on September 23 at 12:30 p.m. Eastern. The session will present the business model, development roadmap, and value proposition of Open-Medicine AI's multi-agentic AI platform for end-to-end therapeutic development.

Led by Panna Sharma, founder and CEO of Open-Medicine AI, the webinar will cover the platform's architecture, its expansion beyond rare cancers into additional disease categories and therapeutic modalities, and its planned subscription and enterprise licensing business model. This announcement signals a strategic move to commercialize AI-driven drug development, potentially accelerating the pace and reducing the cost of bringing new therapies to market.

Lantern Pharma's proprietary RADR artificial intelligence and machine-learning platform integrates large-scale genomic and biological data to identify patients most likely to benefit from its therapies and guide biomarker-driven clinical development. The company's pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. The webinar will provide investors and industry stakeholders with insights into how Open-Medicine AI plans to monetize its technology through subscription and enterprise licensing, a model that could reshape how AI platforms are adopted in biopharma.

For Texas, this development underscores the state's growing prominence in the biotechnology and life sciences sectors. As a hub for innovation, Texas attracts companies that blend advanced technology with healthcare solutions, and Lantern Pharma's efforts could spur further investment and job creation in the region. The integration of AI in drug development not only promises to streamline research but also to personalize treatments, ultimately improving patient outcomes.

Investors and industry observers can access the full press release at https://ibn.fm/U9lmNA. Additionally, the latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN. The webinar is expected to draw attention from those interested in the intersection of AI and oncology, as well as from potential partners and clients seeking to leverage Open-Medicine AI's platform for their own therapeutic development.

The event also highlights the role of BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. Based in Austin, BioMedWire is part of the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions, article syndication to over 5,000 outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit https://www.BioMedWire.com.

As AI continues to transform drug discovery, Lantern Pharma's Open-Medicine AI webinar represents a critical step in showcasing how advanced platforms can be commercialized to benefit patients, investors, and the broader healthcare ecosystem. The implications for Texas include reinforced positioning as a leader in AI-driven biopharma, potential economic growth, and enhanced collaboration opportunities across the life sciences sector.